Amedisys Non Currrent Assets Other vs Total Current Liabilities Analysis

AMED Stock  USD 90.97  0.33  0.36%   
Amedisys financial indicator trend analysis is way more than just evaluating Amedisys prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amedisys is a good investment. Please check the relationship between Amedisys Non Currrent Assets Other and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Non Currrent Assets Other vs Total Current Liabilities

Non Currrent Assets Other vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amedisys Non Currrent Assets Other account and Total Current Liabilities. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Amedisys' Non Currrent Assets Other and Total Current Liabilities is -0.16. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Amedisys, assuming nothing else is changed. The correlation between historical values of Amedisys' Non Currrent Assets Other and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Amedisys are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Currrent Assets Other i.e., Amedisys' Non Currrent Assets Other and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.16
Relationship DirectionNegative 
Relationship StrengthInsignificant

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Total Current Liabilities

Total Current Liabilities is an item on Amedisys balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Amedisys are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Amedisys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amedisys current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.At present, Amedisys' Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 23.95, whereas Tax Provision is forecasted to decline to about 42.3 M.
 2021 2022 2023 2024 (projected)
Gross Profit980.8M962.8M457.1M447.4M
Total Revenue2.2B2.2B2.2B2.3B

Amedisys fundamental ratios Correlations

0.960.870.930.990.110.910.950.60.740.99-0.360.740.950.350.960.290.9-0.090.99-0.160.950.910.370.520.53
0.960.830.810.930.10.980.950.530.610.97-0.420.610.860.21.00.270.88-0.250.97-0.290.850.890.420.380.39
0.870.830.830.850.020.760.890.420.770.86-0.190.770.760.060.840.010.86-0.310.87-0.20.780.820.190.250.25
0.930.810.830.910.160.740.820.580.760.9-0.160.760.90.420.820.440.750.050.93-0.10.930.810.160.570.58
0.990.930.850.910.110.870.930.640.750.98-0.380.750.970.410.930.230.91-0.030.97-0.110.950.90.380.570.58
0.110.10.020.160.110.14-0.060.15-0.140.17-0.03-0.140.020.460.080.190.110.470.12-0.240.020.120.030.460.46
0.910.980.760.740.870.140.910.550.460.93-0.480.460.80.190.980.280.82-0.270.92-0.290.760.840.490.370.37
0.950.950.890.820.93-0.060.910.470.680.94-0.430.680.870.080.960.170.9-0.390.94-0.090.850.910.430.280.29
0.60.530.420.580.640.150.550.470.220.6-0.430.220.690.740.530.110.360.370.580.040.560.370.430.780.78
0.740.610.770.760.75-0.140.460.680.220.690.041.00.750.160.630.080.76-0.020.71-0.170.850.71-0.050.290.3
0.990.970.860.90.980.170.930.940.60.69-0.390.690.920.350.970.250.91-0.10.99-0.170.910.890.40.520.53
-0.36-0.42-0.19-0.16-0.38-0.03-0.48-0.43-0.430.04-0.390.04-0.31-0.1-0.43-0.06-0.40.16-0.330.07-0.22-0.42-1.0-0.15-0.15
0.740.610.770.760.75-0.140.460.680.221.00.690.040.750.160.630.080.76-0.020.71-0.170.850.71-0.050.290.3
0.950.860.760.90.970.020.80.870.690.750.92-0.310.750.480.860.270.80.060.92-0.010.970.830.310.620.63
0.350.20.060.420.410.460.190.080.740.160.35-0.10.160.480.20.20.160.830.30.130.410.090.110.960.96
0.961.00.840.820.930.080.980.960.530.630.97-0.430.630.860.20.260.89-0.250.97-0.280.850.890.430.390.39
0.290.270.010.440.230.190.280.170.110.080.25-0.060.080.270.20.260.020.110.35-0.160.350.30.060.240.25
0.90.880.860.750.910.110.820.90.360.760.91-0.40.760.80.160.890.02-0.20.87-0.210.820.90.40.340.35
-0.09-0.25-0.310.05-0.030.47-0.27-0.390.37-0.02-0.10.16-0.020.060.83-0.250.11-0.2-0.14-0.020.05-0.25-0.160.690.68
0.990.970.870.930.970.120.920.940.580.710.99-0.330.710.920.30.970.350.87-0.14-0.210.930.90.330.480.49
-0.16-0.29-0.2-0.1-0.11-0.24-0.29-0.090.04-0.17-0.170.07-0.17-0.010.13-0.28-0.16-0.21-0.02-0.21-0.1-0.27-0.070.10.09
0.950.850.780.930.950.020.760.850.560.850.91-0.220.850.970.410.850.350.820.050.93-0.10.850.220.560.57
0.910.890.820.810.90.120.840.910.370.710.89-0.420.710.830.090.890.30.9-0.250.9-0.270.850.420.280.29
0.370.420.190.160.380.030.490.430.43-0.050.4-1.0-0.050.310.110.430.060.4-0.160.33-0.070.220.420.160.16
0.520.380.250.570.570.460.370.280.780.290.52-0.150.290.620.960.390.240.340.690.480.10.560.280.161.0
0.530.390.250.580.580.460.370.290.780.30.53-0.150.30.630.960.390.250.350.680.490.090.570.290.161.0
Click cells to compare fundamentals

Amedisys Account Relationship Matchups

Amedisys fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.3B1.6B1.9B2.0B2.1B2.2B
Short Long Term Debt Total326.1M307.0M545.6M537.9M487.2M511.6M
Other Current Liab(3.1M)373.1M291.8M229.3M356.6M374.4M
Total Current Liabilities326.9M456.3M374.3M355.5M473.7M497.4M
Total Stockholder Equity640.5M809.2M931.4M1.1B1.1B1.1B
Property Plant And Equipment Net112.9M117.2M119.7M118.9M130.8M76.0M
Net Debt295.8M225.2M502.9M497.4M360.8M378.8M
Retained Earnings246.4M430.0M639.1M757.7M747.9M785.3M
Accounts Payable31.3M42.7M38.2M43.7M28.2M19.0M
Cash30.3M81.8M42.7M40.5M126.5M132.8M
Non Current Assets Total912.2M1.2B1.5B1.6B1.6B1.6B
Non Currrent Assets Other18.9M19M19.9M(20.4B)5.4M5.7M
Cash And Short Term Investments30.3M81.8M42.7M40.5M126.5M132.8M
Net Receivables237.6M255.1M275.0M296.8M313.4M329.0M
Common Stock Shares Outstanding33.0M33.3M33.0M32.7M32.6M23.4M
Liabilities And Stockholders Equity1.3B1.6B1.9B2.0B2.1B2.2B
Non Current Liabilities Total294.3M300.1M506.4M514.1M466.7M490.0M
Inventory74.4M11.8M13.4M25.2M29.0M30.5M
Other Current Assets8.2M25.0M39.0M51.6M57.1M60.0M
Other Stockholder Equity394.0M379.2M292.3M293.9M318.6M264.1M
Total Liab621.2M756.5M880.6M869.7M940.4M987.4M
Property Plant And Equipment Gross28.1M117.2M216.6M220.2M368.6M350.2M
Total Current Assets350.6M362.0M356.7M389.0M496.9M521.8M
Short Term Debt37.7M40.5M44.2M82.5M88.9M93.3M
Current Deferred Revenue261.1M60M295.2M20.4B106.9M101.5M
Other Liab5.9M33.6M5.0M25.2M29.0M30.5M
Other Assets12K174.6M73.3M39.3M45.2M47.5M
Long Term Debt232.3M204.5M432.1M419.4M361.9M380.0M
Treasury Stock(251.2M)(319.1M)(435.9M)(461.2M)(415.1M)(394.3M)
Property Plant Equipment28.1M23.7M119.7M16.0M18.4M17.5M
Good Will658.5M932.7M1.2B1.3B1.2B1.3B
Intangible Assets64.7M74.2M111.2M101.2M102.7M64.1M
Net Tangible Assets(82.8M)(197.6M)(375.9M)(337.0M)(303.3M)(288.1M)
Noncontrolling Interest In Consolidated Entity1.1M1.5M45.0M55M63.3M66.4M
Retained Earnings Total Equity246.4M430.0M639.1M757.7M871.3M914.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.35)
Earnings Share
2.52
Revenue Per Share
71.004
Quarterly Revenue Growth
0.057
Return On Assets
0.0627
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.